Ropes & Gray advised Verastem Oncology in the deal.Verastem Oncology announced a collaboration to evaluate Mirati Therapeutics’ investigational KRAS inhibitor drug with Verastem’s investigational inhibitor drug in…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
